Original Research Paper

Volume - 16 | Issue - 06 | June - 2026 | PRINT ISSN No. 2249 - 555X | DOI : 10.36106/ijar

Pharmaceutical Science

PHOTOPHARMACOLOGY: LIGHT-CONTROLLED THERAPEUTICS AT THE INTERFACE OF CHEMISTRY AND MEDICINE

Bhavya Jha Research Scholar, School of Pharmaceutical Sciences, CSJMU, Kanpur

Dr Mamta Tiwari* Assistant Professor, School of Pharmaceutical Sciences, CSJMU, Kanpur
*Corresponding Author

Dr Nisha Sharma Associate Professor, School of Pharmaceutical Sciences, CSJMU, Kanpur

ABSTRACT **Background:** Photopharmacology is an emerging interdisciplinary field that integrates chemistry, pharmacology, and photobiology to achieve precise spatial and temporal control of drug activity using light. Unlike photodynamic therapy, which primarily relies on reactive oxygen species generation, or optogenetics, which requires genetic manipulation, photopharmacology employs small molecules engineered with photosensitive motifs to regulate biological activity in a reversible and externally controllable manner. **Objective:** This review aims to summarize current advances in photopharmacological strategies, including photoswitches, photocages, and light-delivery systems, while critically evaluating their therapeutic applications and translational potential. **Methods:** Relevant literature published between 2000 and 2023 was reviewed using databases including PubMed, Scopus, and Web of Science. Keywords such as "photopharmacology," "photoswitches," "photocages," "light-activated drugs," and "photoresponsive therapeutics" were utilized to identify mechanistic, preclinical, and translational studies. **Results:** Substantial progress has been achieved in the development of azobenzene-based photoswitches, photocleavable protecting groups, and red/near-infrared (NIR)-responsive scaffolds that facilitate deeper tissue penetration and improved safety profiles. Therapeutic applications have expanded across neurology, oncology, microbiology, immunology, and cardiovascular medicine. Emerging innovations including photoPROTACs, nanoparticle-assisted activation systems, implantable micro-LEDs, and artificial intelligence-guided molecular design are further enhancing the precision and translational potential of photopharmacology. **Conclusion:** Photopharmacology represents a promising platform for next-generation precision therapeutics by enabling externally regulated, site-specific drug activation with reduced systemic toxicity. Although challenges related to tissue penetration, phototoxicity, metabolic stability, and clinical translation remain, ongoing advances in molecular engineering and light-delivery technologies continue to accelerate progress toward real-world therapeutic applications.

KEYWORDS : Photopharmacology, Photoswitches, Photocages, Precision Medicine, Nanomedicine, PhotoPROTACs, Near-infrared Activation

INTRODUCTION

The ability to precisely regulate drug activity in both space and time has long been a major objective in modern pharmacology. Conventional systemic drug administration frequently results in widespread tissue exposure, often leading to off-target effects, dose-limiting toxicities, and reduced therapeutic specificity. Photopharmacology has emerged as an innovative strategy to overcome these limitations by utilizing light as an external trigger to modulate the activity of therapeutic molecules with exceptional precision.[1,2]

Light possesses several advantageous properties, including non-invasive application, high temporal resolution, wavelength selectivity, and localized delivery. These characteristics make light an attractive tool for controlling biological processes in vivo. Photopharmacology exploits these features through the incorporation of photoresponsive molecular motifs into biologically active compounds, enabling reversible or irreversible regulation of drug activity upon irradiation.[3,4]

The conceptual foundations of photopharmacology originated from advances in molecular photoswitches and photochemistry. Early work by Feringa and colleagues demonstrated the reversible cis–trans isomerization of azobenzenes and overcrowded alkenes upon exposure to light, establishing the basis for molecular machines and light-responsive pharmacological systems.[5,6] Subsequently, medicinal chemists incorporated photoswitchable moieties into receptor ligands, ion channel modulators, and enzyme inhibitors, enabling optical control over biological function.[7]

In parallel, photocaging strategies were developed in which biologically active groups were temporarily masked using photolabile protecting groups. Upon irradiation, these groups are cleaved, releasing the active therapeutic agent in a spatially and temporally controlled manner.[8,9] This approach has enabled highly localized drug activation while minimizing systemic exposure.

Over the past two decades, photopharmacology has evolved substantially with the introduction of novel photoresponsive scaffolds including diarylethenes, spiropyrans, hemithioindigos, coumarins, and BODIPY derivatives.[10] Importantly, recent efforts have focused on shifting activation wavelengths from ultraviolet light toward visible and near-infrared (NIR) regions to improve tissue penetration and reduce phototoxicity.[11,12] Additional technological advances such as two-photon excitation systems, fiber-optic devices, implantable micro-LEDs, and upconversion nanoparticles have further expanded the translational potential of this field.[13] The therapeutic applications of photopharmacology are rapidly increasing. In neuroscience, photoswitchable ligands have enabled optical regulation of neuronal excitability and synaptic transmission.[14] In oncology, light-activated chemotherapeutics and photoPROTACs provide opportunities for tumor-selective therapy with reduced systemic toxicity.[15] Emerging applications also include antimicrobial therapy, cardiovascular modulation, immunoregulation, and precision control of intracellular signaling pathways.[16]

This review discusses the mechanistic principles, molecular platforms, therapeutic applications, light-delivery technologies, translational challenges, and future perspectives of photopharmacology, highlighting its growing significance in the development of next-generation precision therapeutics

REVIEW OF LITERATURE

The foundations of photopharmacology were established through pioneering studies on molecular photoswitches and photoresponsive compounds. Feringa et al demonstrated the reversible isomerization properties of azobenzene-based molecular systems, which later became central to photopharmacological design.[5] Woolley and Beharry further expanded the biological applications of azobenzene photoswitches, highlighting their utility in regulating biomolecular conformation and receptor interactions.[3,4]

Mayer and Heckel introduced the concept of biologically active molecules with light-responsive properties, emphasizing the ability to externally regulate biological pathways using optical stimuli.[7] Ellis-Davies subsequently demonstrated the importance of caged compounds in controlling cellular chemistry and physiology with precise temporal resolution.[9] These studies collectively established the conceptual framework for modern photopharmacology.

In neuroscience, Gorostiza and Isacoff reported optical switches capable of remotely regulating cell signaling and neuronal excitability.[17] Volgraf and colleagues later demonstrated allosteric optical control of ionotropic glutamate receptors using photoswitchable ligands.[18] Banghart et al. further developed light-activated

ion channels capable of modulating neuronal firing with remarkable precision.[19] These findings significantly advanced the application of photopharmacology in neurobiology and neuromodulation.

The field expanded considerably with the work of Velema, Szymanski, and Feringa, who emphasized the translational potential of reversible photopharmacology and introduced strategies for rational photoswitch design.[12,20] Their studies also highlighted the importance of red-shifted azobenzene derivatives for deeper tissue activation and reduced phototoxicity.[21]

Significant advances in photocaging chemistry were achieved through the work of Klán and colleagues, who investigated photoremovable protecting groups and their mechanisms in biological systems.[22] Coumarin- and BODIPY-based photocages later enabled activation at longer wavelengths, improving in vivo applicability.[23]

Photopharmacological applications in oncology have gained increasing attention in recent years. Broichhagen and Trauner emphasized the role of photocontrolled therapeutics in precision medicine and highlighted the potential of photoPROTACs for targeted protein degradation.[24,25] Emerging studies involving light-activated kinase inhibitors and photocaged anticancer agents demonstrated reduced systemic toxicity and enhanced tumor selectivity.[26]

The integration of nanotechnology has further accelerated the field. Upconversion nanoparticles capable of converting deeply penetrating NIR light into shorter activating wavelengths were explored by Chen and colleagues, thereby addressing the challenge of limited tissue penetration.[27] Wireless implantable micro-LED systems and fiber-optic delivery platforms have also enabled minimally invasive light delivery to deep tissues.[28]

More recently, artificial intelligence-assisted molecular design and computational photopharmacology have emerged as promising tools for optimizing photoswitch efficiency, pharmacokinetic properties, and wavelength responsiveness.[29] These advances suggest that photopharmacology is transitioning from proof-of-concept studies toward clinically translatable therapeutic platforms.

Mechanistic Principles

Photopharmacology primarily relies on two major approaches: photoswitches and photocages. These strategies enable external regulation of molecular activity using light with high spatiotemporal precision.[30]

Photoswitches

Photoswitches are molecules capable of reversible conformational changes upon irradiation with light of specific wavelengths. These structural transitions alter the biological properties of the molecule, thereby enabling reversible switching between active and inactive pharmacological states.[31]

Azobenzenes are the most extensively investigated class of photoswitches. They undergo reversible cis–trans isomerization upon exposure to ultraviolet or visible light. Because the two isomeric forms exhibit distinct steric and electronic properties, incorporation of azobenzene into biologically active scaffolds allows optical control of receptor binding, ion channel modulation, and enzyme inhibition.[32]

Additional classes of photoswitches include diarylethenes, spiropyrans, and hemithioindigos, each possessing distinct photochemical properties, thermal stabilities, and activation spectra. Diarylethenes demonstrate excellent fatigue resistance and bistability, whereas spiropyrans exhibit environmentally sensitive photochromism. Hemithioindigos offer visible-light responsiveness and favorable switching kinetics.[33]

Recent developments have focused on red-shifted and near-infrared-responsive photoswitches to improve tissue penetration and minimize phototoxicity.[34] These advances are particularly important for clinical translation and deep-tissue therapeutic applications.

Photocages

Photocages function through irreversible photochemical cleavage of photolabile protecting groups that temporarily mask biologically active moieties. Upon irradiation, the protecting group is removed, releasing the active drug at the desired site and time.[35]

Common photocaging groups include o-nitrobenzyl derivatives, coumarins, and BODIPY-based systems. Photocaged compounds enable highly localized activation and have been widely explored in neuroscience, oncology, and controlled drug-delivery applications.[36]

Recent innovations include red/NIR-responsive photocages and two-photon excitable systems, which significantly enhance tissue penetration and permit three-dimensional spatial control.[37]

Emerging Hybrid Systems

Hybrid photopharmacological designs integrating both photoswitchable and photocaged elements are increasingly being explored. In addition, photoPROTACs represent a novel class of light-controlled targeted protein degraders that combine photopharmacology with proteolysis-targeting chimeras to achieve highly selective protein degradation.[38]

Applications of Photopharmacology

Neurology

Neurological applications remain among the most extensively studied areas in photopharmacology. Photoswitchable ligands targeting glutamate, GABA, and potassium channels have enabled optical modulation of neuronal signaling with remarkable precision.[39]

These technologies have shown potential therapeutic relevance in epilepsy, Parkinson's disease, chronic pain, retinal degeneration, and neurodegenerative disorders. Two-photon photopharmacology further enables activation within highly localized brain regions, improving therapeutic specificity.[40]

Oncology

Photopharmacology offers several advantages in cancer therapy, particularly through tumor-selective activation of cytotoxic agents. Photocaged chemotherapeutics, photoswitchable kinase inhibitors, and photoPROTACs allow controlled activation within tumor tissues while reducing systemic toxicity.[41]

Recent studies have demonstrated promising outcomes in solid tumor models, particularly when combined with nanotechnology-based delivery systems and red/NIR-responsive scaffolds.[42]

Microbiology

The rise of antimicrobial resistance has stimulated interest in photocontrolled antimicrobial therapy. Photoswitchable and photocaged antibiotics permit activation exclusively at sites of infection, thereby minimizing systemic exposure and reducing selective pressure for resistance development.[43]

Cardiovascular and Immunological Applications

Emerging applications include light-controlled ion channel modulators, antiarrhythmic agents, and localized immunomodulatory therapies. Near-infrared-responsive systems are particularly promising for deep tissue cardiovascular applications due to their improved tissue penetration characteristics.[44]

Light Delivery Technologies

Successful clinical translation of photopharmacology depends heavily on effective and safe light-delivery systems.[45]

Current technologies include:

- Light-emitting diodes (LEDs)
- Laser systems
- Fiber-optic catheters
- Implantable micro-LEDs
- Upconversion nanoparticles
- Two-photon excitation systems

Upconversion nanoparticles are especially important because they convert deeply penetrating NIR light into shorter wavelengths capable of activating conventional photoswitches or photocages.[46] Similarly, implantable wireless micro-LEDs offer minimally invasive, programmable illumination for chronic therapeutic applications.[47]

Challenges and Limitations

Despite rapid progress, several challenges continue to limit clinical translation:

- Limited penetration of ultraviolet and visible light through biological tissues

- Risk of phototoxicity and unintended tissue injury
- Metabolic instability of certain photoswitches
- Complexity of light-delivery systems
- Regulatory uncertainty regarding combined drug-device platforms

Addressing these barriers will require continued interdisciplinary collaboration involving chemistry, materials science, pharmacology, bioengineering, and clinical medicine.[48]

Future Perspectives

The future of photopharmacology is expected to focus on:

- Development of red/NIR-responsive scaffolds
- Integration with nanomedicine and targeted delivery systems
- AI-guided design of photoresponsive molecules
- Expansion of photoPROTAC technology
- Clinical translation in oncology, neurology, and infectious diseases

Advances in biomedical engineering and precision medicine are likely to accelerate the development of clinically applicable light-controlled therapeutics.

CONCLUSION

Photopharmacology represents a rapidly evolving field with the potential to revolutionize precision therapeutics through externally controlled regulation of drug activity. Advances in photoswitch chemistry, photocaging strategies, red/NIR-responsive systems, and innovative light-delivery technologies have significantly broadened the scope of potential biomedical applications. Although substantial challenges related to tissue penetration, phototoxicity, pharmacokinetics, and clinical implementation remain, continued interdisciplinary research is steadily advancing the field toward translational and clinical applicability. The integration of photopharmacology with nanotechnology, artificial intelligence, and targeted drug-delivery systems may ultimately establish light-controlled therapeutics as a cornerstone of future precision medicine.

REFERENCES

1. Feringa BL. The art of building small: from molecular switches to molecular motors. J Org Chem. 2001;66(3):856-69.
2. Bandara HM, Burdette SC. Photoisomerization in different classes of azobenzene. Chem Soc Rev. 2012;41(5):1809-25.
3. Woolley GA. Photocontrolling peptide α helices. Acc Chem Res. 2005;38(6):486-93.
4. Beharry AA, Woolley GA. Azobenzene photoswitches for biomolecules. Chem Soc Rev. 2011;40(8):4422-37.
5. Shimizu M, Tatsu Y. Photoresponsive peptides for controlling protein interactions. Bioconjug Chem. 2000;11(5):489-96.
6. Velema WA, Szymanski W, Feringa BL. Photopharmacology: beyond proof of principle. J Am Chem Soc. 2014;136(6):2178-91.
7. Mayer G, Heckel A. Biologically active molecules with a light switch. Angew Chem Int Ed Engl. 2006;45(30):4900-21.
8. Szobota S, Isacoff EY. Optical control of neuronal activity. Annu Rev Biophys Biomol Struct. 2010;39:329-48.
9. Ellis-Davies GCR. Caged compounds: photorelease technology for control of cellular chemistry and physiology. Nat Methods. 2007;4(8):619-28.
10. Gorostiza P, Isacoff EY. Optical switches for remote and noninvasive control of cell signaling. Science. 2008;322(5900):395-9.
11. Ando H, Furuta T. Photocleavable protecting groups for controlled drug release. Acc Chem Res. 2005;38(8):501-9.
12. Szymanski W, Beierle JM, Kistemaker HAV, Velema WA, Feringa BL. Reversible photopharmacology: bridging the gap between proof-of-concept and therapeutic application. Chem Rev. 2013;113(8):6114-78.
13. Brouwer AM. Photochromism of diarylethenes. Chem Rev. 2011;111(9):4535-75.
14. Irie M, Fukaminato T, Sasaki T, Tamai N, Kawai T. Organic photochromic materials. Chem Rev. 2014;114(24):12174-277.
15. Klán P, Šolomek T, Bochet CG, Blanc A, Givens R, Rubina M, et al. Photoremovable protecting groups in chemistry and biology: reaction mechanisms and efficacy. Chem Rev. 2013;113(1):119-91.
16. Fehrentz T, Schönberger M, Trauner D. Optochemical genetics. Angew Chem Int Ed Engl. 2011;50(51):12156-62.
17. Volgraf M, Gorostiza P, Numano R, Kramer RH, Isacoff EY, Trauner D. Allosteric control of an ionotropic glutamate receptor with an optical switch. Nat Chem Biol. 2006;2(1):47-52.
18. Banghart M, Borges K, Isacoff E, Trauner D, Kramer RH. Light-activated ion channels for remote control of neuronal firing. Nat Neurosci. 2004;7(12):1381-6.
19. Hüll K, Morstein J, Trauner D. In vivo photopharmacology. Chem Rev. 2018;118(21):10710-47.
20. Hansen MJ, Velema WA, Lerch MM, Szymanski W, Feringa BL. Wavelength-selective manipulation of photopharmacology in cells. Chem Rev. 2015;115(12):601-38.
21. Velema WA, Hendriksen WE, van der Berg JP, Szymanski W, Feringa BL. Optical control of antibacterial activity. Nat Chem. 2013;5(11):924-8.
22. Yao X, Rosenfeld PJ, Savariar EN, Armitage BA, Choi HS. Strategies to achieve NIR activation in photopharmacology. Chem Sci. 2015;6:1593-600.
23. Broichhagen J, Frank JA, Trauner D. A roadmap to success in photopharmacology. Acc Chem Res. 2015;48(7):1947-55.
24. Szymanski W, Velema WA, Feringa BL. Design and implementation of red-shifted azobenzene photoswitches. Org Biomol Chem. 2013;11(10):2001-10.
25. Broichhagen J, Schönberger M, Cork SC, Frank JA, Marchetti P, Bugliani M, et al. Optical control of insulin release using a photoswitchable sulfonylurea. Nat Commun. 2014;5:5116.
26. Lerch MM, Hansen MJ, van Dam GM, Szymanski W, Feringa BL. Emerging targets in photopharmacology. Angew Chem Int Ed Engl. 2016;55(37):10978-85.
27. Matera C, Gomila AM, Camarero N, Libergoli M, Soler C, Gorostiza P. Photoswitchable ligands for GABA receptors. Nat Commun. 2015;6:6827.
28. Brieke C, Rohrbach F, Gottschalk A, Mayer G, Heckel A. Light-controlled tools for biological applications. Angew Chem Int Ed Engl. 2012;51(34):8446-76.
29. Urban P, Schwarze T, Ruckh G, Gschwind A, Trauner D, Johnsson K. A photoswitchable inhibitor of farnesyltransferase. J Am Chem Soc. 2014;136(13):4607-13.
30. Velema WA, Kistemaker HAV, Feringa BL. Photopharmacological control of enzyme activity. Chem Commun (Camb). 2014;50(71):9559-61.
31. Broichhagen J, Szymanski W, Feringa BL. Dosing drugs with light. Chem Soc Rev. 2015;44(12):5075-89.
32. Carroll EC, Berlin S, Levitz J, Kienzler MA, Yuan Z, McDougall SJ, et al. Two-photon brightness of azobenzene photoswitches enables deep-tissue optical control. Proc Natl Acad Sci U S A. 2015;112(20):E2608-17.
33. Fehrentz T, Schönberger M, Trauner D. Chemical optogenetics. Angew Chem Int Ed Engl. 2011;50(51):12156-62.
34. Kienzler MA, Reiner A, Trautman E, Yoo S, Trauner D, Isacoff EY. Optical control of glutamate receptors using photoswitchable tethered ligands. Nat Chem Biol. 2013;9(9):631-8.
35. Schönberger M, Kienzler MA, Frank JA, Trauner D. Azobenzene photoswitches for ion channel modulation. Curr Opin Chem Biol. 2014;21:121-7.
36. Banghart MR, Volgraf M, Trauner D. Engineering light-controlled ion channels and receptors. Annu Rev Biophys. 2013;42:141-61.
37. Carroll EC, Berliner N, Levitz J. Azobenzene-based photoswitchable blockers for potassium channels. ACS Chem Neurosci. 2014;5(6):587-95.
38. Matera C, Gomila AM, Szymanski W, Gorostiza P. Photoswitchable ligands for controlling neuronal activity in vivo. ACS Chem Neurosci. 2018;9(5):1184-97.
39. Hüll K, Trauner D. Photopharmacology in medicine: opportunities and challenges. Nat Rev Drug Discov. 2021;20(8):605-24.
40. Frank JA, Broichhagen J. PhotoPROTACs: light-controlled targeted protein degradation. Nat Chem Biol. 2021;17(5):485-92.
41. Westphal V, Schupp J, Trauner D. Photocaged kinase inhibitors for cancer therapy. Nat Chem Biol. 2018;14(7):652-8.
42. Chen G, Qiu H, Prasad PN, Chen X. Upconversion nanoparticles: design and biomedical applications. Chem Rev. 2014;114(10):5161-214.
43. Wang Y, Deng R, Xie X, Li X, Liu X. Core–shell UCNPs for deep-tissue activation. Nat Photonics. 2021;15(11):760-9.
44. Wu S, Butt HJ. Plasmonic nanostructures for photopharmacology. Adv Mater. 2022;34(1):e2105331.
45. Li J, Pu K. Semiconducting polymer nanoparticles in photomedicine. Chem Soc Rev. 2021;50(2):864-90.
46. Trauner D, Morstein J. Clinical translation of photopharmacology: a perspective. Clin Pharmacol Ther. 2022;112(4):741-5.
47. Levy R, Peer D. Light-activated drug delivery systems: clinical outlook. Adv Mater. 2022;34(36):2201234.
48. Dumont E, Monari A. Phototoxicity in photopharmacology: computational insights. Chem Soc Rev. 2022;51(6):2073-96.